Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

3.29

Mkt cap

11M

Volume

136K

High

3.57

P/E Ratio

-0.01

52-wk high

152.40

Low

3.29

Div yield

N/A

52-wk low

1.80

Cingulate shares have resumed trading after a temporary halt. This development could impact investor sentiment and stock price movements in the short term.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:45 pm

Cingulate shares have been halted to the upside, with the stock now up by 202.98%.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 5:35 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 2%. Walmart reported strong Q2 results and raised full-year guidance. Cingulate, AST SpaceMobile, and SciSparc saw significant stock price increases, while Turnstone Biologics, SIGA Technologies, and Terran Orbital experienced sharp declines.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 4:27 pm

U.S. stocks surged with the Dow Jones gaining over 500 points, driven by a 1% rise in U.S. retail sales for July. Consumer discretionary shares led the gains, while utilities lagged. Notable stock movements included significant gains for Cingulate Inc., VS MEDIA Holdings Limited, and SciSparc Ltd., and sharp declines for Turnstone Biologics Corp., SIGA Technologies, Inc., and Terran Orbital Corporation.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 1:46 pm

Cingulate shares are trading higher after the company was granted European patent No. 3261625 for CTx-1301, its lead asset for the treatment of ADHD.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:32 pm

On August 15th, Walmart (WMT) raised its FY25 adjusted EPS outlook, Cingulate (CING) received a European patent for its lead asset CTx-1301, and Airship AI Holdings (AISP) reported a year-over-year increase in Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:14 pm

Cingulate has received a European patent for its lead asset CTx-1301 (Dexmethylphenidate) for the treatment of ADHD. The patent, granted on August 14, 2024, covers up to 30 European territories, including the UK. Cingulate also holds patents in Australia, Canada, and Israel, with pending patents in Hong Kong, South Korea, and the US.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:46 am

Cingulate shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 2:27 pm

Cingulate Management plans to seek additional capital through various means, including non-dilutive capital via potential licensing opportunities both inside and outside the US, as well as additional equity or debt capital.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:49 am

Cingulate had $0.4M in cash and cash equivalents. On July 1, 2024, Cingulate received net proceeds of $1.6M from a warrant inducement. Management believes this cash will support operating and development costs late into Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:48 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.